174 related articles for article (PubMed ID: 38433914)
1. A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses.
Gonçalves MP; Farah R; Bikorimana JP; Abusarah J; El-Hachem N; Saad W; Talbot S; Stanga D; Beaudoin S; Plouffe S; Rafei M
iScience; 2024 Mar; 27(3):109248. PubMed ID: 38433914
[TBL] [Abstract][Full Text] [Related]
2. UM171A-induced ROS promote antigen cross-presentation of immunogenic peptides by bone marrow-derived mesenchymal stromal cells.
Salame N; Bikorimana JP; El-Hachem N; Saad W; Kurdi M; Zhao J; Eliopoulos N; Shammaa R; Rafei M
Stem Cell Res Ther; 2022 Jan; 13(1):16. PubMed ID: 35012668
[TBL] [Abstract][Full Text] [Related]
3. Local delivery of accutox
Bikorimana JP; El-Hachem N; Abusarah J; Gonçalves MP; Farah R; Mandl GA; Talbot S; Beaudoin S; Stanga D; Plouffe S; Rafei M
J Transl Med; 2024 Jun; 22(1):532. PubMed ID: 38831284
[TBL] [Abstract][Full Text] [Related]
4. Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice.
Abusarah J; Khodayarian F; El-Hachem N; Salame N; Olivier M; Balood M; Roversi K; Talbot S; Bikorimana JP; Chen J; Jolicoeur M; Trudeau LE; Kamyabiazar S; Annabi B; Robert F; Pelletier J; El-Kadiry AE; Shammaa R; Rafei M
Cell Rep Med; 2021 Dec; 2(12):100455. PubMed ID: 35028603
[TBL] [Abstract][Full Text] [Related]
5. Promoting antigen escape from dendritic cell endosomes potentiates anti-tumoral immunity.
Bikorimana JP; Salame N; Beaudoin S; Balood M; Crosson T; Abusarah J; Talbot S; Löbenberg R; Plouffe S; Rafei M
Cell Rep Med; 2022 Mar; 3(3):100534. PubMed ID: 35492876
[TBL] [Abstract][Full Text] [Related]
6. Thymoproteasome-Expressing Mesenchymal Stromal Cells Confer Protective Anti-Tumor Immunity
Bikorimana JP; El-Hachem N; El-Kadiry AE; Abusarah J; Salame N; Shammaa R; Rafei M
Front Immunol; 2020; 11():596303. PubMed ID: 33542714
[TBL] [Abstract][Full Text] [Related]
7. LSD1 Inhibition Enhances the Immunogenicity of Mesenchymal Stromal Cells by Eliciting a dsRNA Stress Response.
Mardani F; Saad W; El-Hachem N; Bikorimana JP; Kurdi M; Shammaa R; Talbot S; Rafei M
Cells; 2022 Jun; 11(11):. PubMed ID: 35681511
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties.
François M; Romieu-Mourez R; Stock-Martineau S; Boivin MN; Bramson JL; Galipeau J
Blood; 2009 Sep; 114(13):2632-8. PubMed ID: 19654411
[TBL] [Abstract][Full Text] [Related]
9. Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
Gatti-Mays ME; Gameiro SR; Ozawa Y; Knudson KM; Hicks KC; Palena C; Cordes LM; Steinberg SM; Francis D; Karzai F; Lipkowitz S; Donahue RN; Jochems C; Schlom J; Gulley JL
Front Oncol; 2020; 10():581801. PubMed ID: 33747894
[TBL] [Abstract][Full Text] [Related]
10. The
Bikorimana JP; El-Hachem N; Abusarah J; Eliopoulos N; Talbot S; Shammaa R; Rafei M
iScience; 2022 Dec; 25(12):105537. PubMed ID: 36437872
[TBL] [Abstract][Full Text] [Related]
11. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
[TBL] [Abstract][Full Text] [Related]
12. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
13. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
[TBL] [Abstract][Full Text] [Related]
14. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
15. An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial.
Charles J; Chaperot L; Hannani D; Bruder Costa J; Templier I; Trabelsi S; Gil H; Moisan A; Persoons V; Hegelhofer H; Schir E; Quesada JL; Mendoza C; Aspord C; Manches O; Coulie PG; Khammari A; Dreno B; Leccia MT; Plumas J
Oncoimmunology; 2020; 9(1):1738812. PubMed ID: 32313721
[TBL] [Abstract][Full Text] [Related]
16. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.
Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG
Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848
[TBL] [Abstract][Full Text] [Related]
17. If it ain't broke, break it: facilitating antigen cross-presentation.
Rodríguez-Silvestre P; Kozik P
Trends Mol Med; 2022 Apr; 28(4):251-252. PubMed ID: 35288004
[TBL] [Abstract][Full Text] [Related]
18. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
19. NLGP counterbalances the immunosuppressive effect of tumor-associated mesenchymal stem cells to restore effector T cell functions.
Ghosh T; Nandi P; Ganguly N; Guha I; Bhuniya A; Ghosh S; Sarkar A; Saha A; Dasgupta S; Baral R; Bose A
Stem Cell Res Ther; 2019 Sep; 10(1):296. PubMed ID: 31547863
[TBL] [Abstract][Full Text] [Related]
20. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
